Anesiva Announces Clinical Data From Phase 1 Trial Of 1207
Fri, 19 Jan 2007 08:00 AM EST
... Anesiva, Inc. (Nasdaq: ANSV) announced today clinical data from a Phase 1 safety study of product candidate 1207, which was being tested as a topical anesthetic for treatment of neuropathic patients. 1207 achieved the primary endpoint of the study of safety and tolerability. In the studied population of healthy volunteers, no clear anesthetic effect of 1207 was demonstrated. [click link for full article] ...
Related Topics
- Clinical Trials
- Data & Statistics
- Data Analysis
- National Data
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Mining
- Tarceva
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Clinical Growth Charts
- Bevacizumab Injection
- Crohn's Disease
- Pancreatic Cancer
- Logging
- Patient Issues
- Chemical Safety
- Visualization
- Influenza Surveillance Data

Not Signed In -

